Publications by authors named "Myrto Cheila"
Introduction: Hepatitis B reactivation and administration of prophylactic antiviral treatment are considered in patients with autoimmune inflammatory rheumatic diseases (AIIRD) undergoing immunosuppressive/immunomodulatory treatment. Data are more robust for rheumatoid arthritis patients receiving bDMARDs but are limited for other AIIRD and drug categories.
Methods: Adult patients with AIIRD (inflammatory arthritis [IA] or connective tissue diseases [CTD]) and documented chronic or resolved HBV infection (defined as serum HBsAg positivity or anti-HBcAb positivity in the case of HBsAg non-detection respectively), followed-up in six rheumatology centers in Greece and Italy, were included.
Article Synopsis
- The study aimed to evaluate the effectiveness of conventional immunosuppressive treatments in patients with lupus nephritis (LN) by assessing response rates over one year and identifying predictors of non-response.
- Involving 140 patients, the research found that around 69.2% achieved a positive response by 12 months, although 20% needed changes in their treatment due to insufficient progress.
- Increased chronicity at the start was linked to a higher chance of not responding to treatment, indicating that both chronicity and histological activity are important factors influencing patient outcomes.
T cell checkpoint inhibitors targeting Programmed cell Death protein-1 (PD-1) have emerged as novel immunotherapy agents showing remarkable efficacy in head and neck squamous cell carcinoma (HNSCC). Despite important clinical benefits, they are associated with side effects that occur as a consequence of general immunological stimulation due to loss of T cell inhibition. Herein, we report the unusual case of inflammatory arthritis induced by anti-PD-1 agent pembrolizumab.
View Article and Find Full Text PDF